智通财经APP讯，药明巨诺-B(02126)发布公告，公司于2025年3月19日与Juno(公司主要股东之一及关连人士)订立材料转让协议，据此，Juno向公司(或其指定联属公司)转让总价值不低于100万美元的若干载体，以换取公司同意Juno使用初步s ...

公告称，公司已与Juno建立紧密的合作关系 ... 公司必须能够利用其在CAR-T研发、制造及商业化方面的优势，以借助与百时美施贵宝这一现有关系 ...

Juno Therapeutics could be set for a remarkable comeback in CAR-T therapy, after encouraging trial data on a new candidate suggests it could be prove to be the best in class. The Seattle-based ...

The potential pharma companies see in this type of therapy was demonstrated last year, when Juno signed a decade-long, billion-dollar deal with Celgene to develop CAR-T therapies. Hans Bishop ...

Juno Therapeutics Inc. and Wuxi Apptec Co. Ltd., and CASI Pharmaceuticals Inc. and Juventas Cell Therapy Ltd. As of Jan. 31, 2024, there were more than 300 CAR T trials registered in China, surpassing ...